每(mei)經AI快訊，9月11日，恒瑞(rui)醫(yi)藥公(gong)(gong)告，子(zi)公(gong)(gong)司成都盛迪醫(yi)藥收到(dao)國(guo)家藥監局(ju)核準(zhun)簽發的(de)藥品注(zhu)冊證書，地夸(kua)磷索鈉滴眼(yan)液(ye)(ye)（單劑量）獲(huo)批上市。公(gong)(gong)司同(tong)時(shi)公(gong)(gong)告，子(zi)公(gong)(gong)司福建盛迪醫(yi)藥收到(dao)國(guo)家藥監局(ju)核準(zhun)簽發關于HRS-7450注(zhu)射液(ye)(ye)的(de)藥物臨床試(shi)驗批準(zhun)通知書，將于近期開展(zhan)臨床試(shi)驗。HRS-7450是下一代(dai)溶(rong)栓藥物，溶(rong)栓同(tong)時(shi)不(bu)影響機體自身凝血(xue)和纖溶(rong)平衡(heng)，潛在出血(xue)風(feng)險(xian)低，有望延長溶(rong)栓治療時(shi)間窗(chuang)。